MBNL1 and Alzheimer disease: None of the investigated transcripts were changed in muscles from patients with SELENON-related MmD (Fig. 4D) nor from patients with AD-RYR1-related CCD (Fig. 4E) though in AR RYR1 MmD/CNM MBNL1 levels were reduced though the fold change did not achieve significance (the mean log2-fold change was −0.57 adjusted P = 0.06; Fig. 4F).